Jiang Xiaoyun, Hua Chunting, Feng Chenxi, Cheng Hao
Department of Dermatology, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Front Pharmacol. 2025 Jul 21;16:1580170. doi: 10.3389/fphar.2025.1580170. eCollection 2025.
Acute generalized exanthematous pustulosis (AGEP) is a severe cutaneous drug reaction that typically resolves rapidly following withdrawal of the offending drug and administration of systemic corticosteroids. Infliximab, a biologic agent that inhibits TNF-α, is widely used in the treatment of various inflammatory diseases. Individuals with specific genetic risk factors may be more susceptible to severe drug-induced cutaneous reactions. Here, we report the first case of successful infliximab treatment in a pregnant woman with IL17A and IL36RN mutations who developed severe AGEP after 24 days of hydroxychloroquine use and failed to respond to conventional therapy.
急性泛发性脓疱性皮病（AGEP）是一种严重的皮肤药物反应，通常在停用致病药物并给予全身性皮质类固醇后迅速消退。英夫利昔单抗是一种抑制TNF-α的生物制剂，广泛用于治疗各种炎症性疾病。具有特定遗传风险因素的个体可能更容易发生严重的药物性皮肤反应。在此，我们报告首例成功治疗的病例，一名携带IL17A和IL36RN突变的孕妇在使用羟氯喹24天后发生严重AGEP，对传统治疗无反应，但使用英夫利昔单抗治疗成功。
